Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Description

This platform trial will evaluate various immunotherapy combinations given in the neo-adjuvant and adjuvant setting in patients with surgically resectable pancreatic ductal adenocarcinoma.

Conditions

Pancreatic Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This platform trial will evaluate various immunotherapy combinations given in the neo-adjuvant and adjuvant setting in patients with surgically resectable pancreatic ductal adenocarcinoma.

A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Condition
Pancreatic Cancer
Intervention / Treatment

-

Contacts and Locations

Baltimore

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States, 21231-2410

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Newly diagnosed or clinically-suspected adenocarcinoma of the head, neck, or uncinate process of the pancreas
  • * Tumor must be surgically resectable
  • * ECOG Performance Status of 0 to 1
  • * Adequate organ function as defined by study-specified laboratory tests
  • * Must agree to use acceptable form of birth control
  • * Received any type of anti-cancer treatment or immunotherapy for pancreas cancer
  • * History of autoimmune disease (Graves or Hashimoto's disease, vitiligo, and type I diabetes are allowed)
  • * Systemically steroid use within 14 days
  • * Evidence of active infection
  • * Pregnant or lactating
  • * Diagnosed with another cancer or myeloproliferative disorder (some exceptions)
  • * History of severe hypersensitivity reaction to any monoclonal antibody or known component of the study drugs
  • * Known history of infection with HIV, hepatitis B, or hepatitis C
  • * Oxygen saturation of \<92% on room air by pulse oximetry
  • * On home oxygen

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,

Ana De Jesus-Acosta, MD, PRINCIPAL_INVESTIGATOR, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Study Record Dates

2026-08-31